Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-25-025679
Filing Date
2025-05-15
Accepted
2025-05-15 09:15:42
Documents
75
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q mrsn-20250331.htm   iXBRL 10-Q 1254231
2 EX-31.1 exhibit31110-qfy2025q1.htm EX-31.1 11097
3 EX-31.2 exhibit31210-qfy2025q1.htm EX-31.2 11115
4 EX-32.1 exhibit32110-qfy2025q1.htm EX-32.1 5736
  Complete submission text file 0001628280-25-025679.txt   5857401

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrsn-20250331.xsd EX-101.SCH 40670
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mrsn-20250331_cal.xml EX-101.CAL 49320
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrsn-20250331_def.xml EX-101.DEF 173382
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrsn-20250331_lab.xml EX-101.LAB 542570
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrsn-20250331_pre.xml EX-101.PRE 386786
78 EXTRACTED XBRL INSTANCE DOCUMENT mrsn-20250331_htm.xml XML 586877
Mailing Address 840 MEMORIAL DRIVE CAMBRIDGE MA 02139
Business Address 840 MEMORIAL DRIVE CAMBRIDGE MA 02139 617-498-0020
Mersana Therapeutics, Inc. (Filer) CIK: 0001442836 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38129 | Film No.: 25949207
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)